Dr. Wenxiang Wang 王文祥
Chief Physician
Department of Thoracic Surgery II, Hunan Cancer Hospital, Changsha
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Surgical and minimally invasive treatment of thoracic surgery diseases.
Dr. Wang is Chief Physician and Director of the Second Department of Thoracic Surgery at Hunan Cancer Hospital. Dr. Wang holds a PhD in Cardiothoracic Surgery from Central South University Xiangya School of Medicine (2007) and completed fellowships at Henri Mondor Hospital in Paris and Cedars-Sinai Medical Center in the US.
Professional roles
- Member, Thoracic and Cardiovascular Surgery Committee, Hunan Medical Association
- Member, Integrated Traditional Chinese and Western Medicine Committee, Hunan Province
- Member, Tumor Rehabilitation Professional Committee, Hunan Province
Name order: in Chinese the family name comes first (Wang Wenxiang). Papers usually list the name as Wenxiang Wang or Wang W.
Selected publications
63 papers on PubMed matched by name and affiliation; 19 as first or senior author since 2016. Most recent first- or senior-author papers:
- Medicine (Baltimore), 2025 (senior author): Distinguishing MPLCs from IPMs using NGS-based molecular algorithms and histological assessment: A systematic review and validation study. PubMed 39993063
- Mikrochim Acta, 2023 (senior author): Quantitative biochemical phenotypic heterogeneity of senescent macrophage at a single cell level by Synchrotron Radiation Fourier Transform Infrared Microspectroscopy. PubMed 37768393
- Medicine (Baltimore), 2023 (senior author): High FN1 expression is associated with poor survival in esophageal squamous cell carcinoma. PubMed 37026938
- Cancer Cell Int, 2022 (senior author): Oncogenic roles of the lncRNA LINC00460 in human cancers. PubMed 35906593
- Front Oncol, 2022 (senior author): Perioperative Outcomes of Video-Assisted Thoracoscopic Surgery Versus Open Thoracotomy After Neoadjuvant Chemoimmunotherapy in Resectable NSCLC. PubMed 35712494
- Front Immunol, 2021 (senior author): What Happens to the Immune Microenvironment After PD-1 Inhibitor Therapy?. PubMed 35003090
- J Int Med Res, 2021 (senior author): Next-generation sequencing revealed synchronous double primary lung squamous carcinoma: a case report. PubMed 34038210
- Biomark Res, 2020 (senior author): LncRNA SNHG16 as a potential biomarker and therapeutic target in human cancers. PubMed 32944244
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion